Tevogen Inc. (NASDAQ: TVGN) changes name from Tevogen Bio Holdings
Rhea-AI Filing Summary
Tevogen Bio Holdings Inc., a Delaware corporation, has amended its Certificate of Incorporation to change its name to Tevogen Inc. A Certificate of Amendment was filed on July 29, 2026, and the name change became effective on July 30, 2026. The board also approved a conforming amendment to the Amended and Restated Bylaws, with no other bylaw changes.
The company’s common stock, par value $0.001 per share, and public warrants, exercisable at $575 per share, continue to trade on the Nasdaq Global Market under their existing ticker symbols. The CUSIP numbers 88165K200 for common stock and 88165K119 for warrants are unchanged, and the name change does not affect the rights of security holders.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.03, 9.01
2 items
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Name change effective date: July 30, 2026
Certificate of Amendment filing date: July 29, 2026
Par value per common share: $0.001 per share
+3 more
6 metrics
Name change effective date
July 30, 2026
Effective date of change from Tevogen Bio Holdings Inc. to Tevogen Inc.
Certificate of Amendment filing date
July 29, 2026
Date the Certificate of Amendment to the Certificate of Incorporation was filed
Par value per common share
$0.001 per share
Par value of common stock listed on the Nasdaq Global Market
Warrant exercise price
$575 per share
Exercise price of public warrants for shares of common stock
Common stock CUSIP
88165K200
CUSIP number for common stock remains unchanged after the name change
Warrants CUSIP
88165K119
CUSIP number for public warrants remains unchanged after the name change
Key Terms
Certificate of Amendment, Amended and Restated Bylaws, CUSIP, emerging growth company
4 terms
Certificate of Amendment regulatory
"filed a certificate of amendment to its Certificate of Incorporation"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
Amended and Restated Bylaws regulatory
"an amendment to the Company’s Amended and Restated Bylaws"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
CUSIP financial
"the CUSIP numbers for the Company’s common stock and public warrants"
A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.
emerging growth company regulatory
"Emerging growth company On July 29, 2026, Tevogen Bio"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What corporate change did Tevogen Inc. (TVGN) report?
Tevogen Inc. reported amending its Certificate of Incorporation to change its corporate name from Tevogen Bio Holdings Inc. to Tevogen Inc.. The Certificate of Amendment was filed on July 29, 2026, with the name change effective July 30, 2026.
When does the Tevogen Inc. (TVGN) name change become effective?
The name change from Tevogen Bio Holdings Inc. to Tevogen Inc. became effective on July 30, 2026. The Certificate of Amendment implementing the change was filed one day earlier, on July 29, 2026, with the Delaware authorities.
How does the Tevogen Inc. (TVGN) name change affect its Nasdaq listings?
Tevogen Inc.’s common stock and public warrants continue to trade on the Nasdaq Global Market under their existing ticker symbols. The name change does not alter the Nasdaq listing status or the trading symbols associated with the company’s securities.
Were the CUSIP numbers for Tevogen Inc. (TVGN) securities changed?
No. The CUSIP number for the company’s common stock remains 88165K200, and the CUSIP for its public warrants remains 88165K119. The filing specifies that these identifiers are unchanged following the corporate name change.
What are the key terms of Tevogen Inc. (TVGN) public warrants?
Tevogen Inc.’s public warrants are exercisable for shares of common stock at an exercise price of $575 per share. The name change and related amendments do not modify these warrant terms or their existing Nasdaq trading status.